Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899067 | 0.78 | KDM4E (0.44) | FFAR1HDAC6L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25810607 | 0.72 | PTPN11 (0.35) | PTPN11PDCD1CD274 | |
| SCHEMBL20899131 | 0.71 | FFAR1 (0.36) | FFAR1HDAC6P4HTMMAP4K4L3MBTL1 | |
| Propionic Acid SCHEMBL20899011 | 0.70 | CCR4 (0.33) | PTPN11FFAR1PDCD1CD274ALDH1A1 | |
| SCHEMBL20909030 | 0.69 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGD | |
| SCHEMBL24986582 | 0.65 | KMO (0.39) | PTPN11KDM4EALDH1A1 | |
| SCHEMBL30185163 | 0.65 | KMO (0.39) | PTPN11KDM4EALDH1A1 | |
| SCHEMBL30495472 | 0.64 | CD274 (0.33) | PTPN11PDCD1CD274 | |
| SCHEMBL27080475 | 0.63 | LMNA (0.35) | PTPN11 | |
| SCHEMBL2561240 | 0.61 | FFAR1 (0.54) | FFAR1TBXAS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200339552-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-10-29 | — | — | US | disclosed |
| EP-3694848-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019075265-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339552-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885FFAR1 1710/4885HDAC6 1045/4885 |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885FFAR1 1710/4885HDAC6 1045/4885 |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885FFAR1 1710/4885HDAC6 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.